By suppressing transcriptional reprogramming, CDK8/19 inhibitors (CDK8/19i) showed a unique ability to suppress the growth of metastases preferentially to primary tumors, as reported for colon cancer (12). Here, CDK8 is linked to malignant colon neoplasm.